<DOC>
	<DOC>NCT00738257</DOC>
	<brief_summary>The purpose of the study was to evaluate the effect of Pamidronate on bone mineral density loss and fracture rates up to 2 years, in post renal-transplant subjects on a Ciclosporin A and glucocorticoid based immunosuppressive regimen.</brief_summary>
	<brief_title>A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.</brief_title>
	<detailed_description />
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>1. First or second kidney transplant recipients, aged 1875 years, PTH &gt; 150 pg/ml 2. De novo patients scheduled to receive ciclosporin A and prednisolone based immunosuppression. 1. Previous or current bone disease unrelated to end stage renal failure. 2. Patients with PTH &lt; 150pg/ml who may be at risk of adynamic bone disease. 3. Treatment at any time with a bisphosphonate. 4. d. Calcitonin treatment during the previous month. 5. Malignancy (current or history within last 5 years) 6. Pregnancy or lactation, or women of childbearing potential unwilling to use an effective form of contraception for the 12 month duration of the study. Protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Renal</keyword>
	<keyword>transplant,</keyword>
	<keyword>pamidronate,</keyword>
	<keyword>ciclosporin,</keyword>
	<keyword>Ciclosporin A,</keyword>
	<keyword>steroids,</keyword>
	<keyword>bone mineral density,</keyword>
	<keyword>fracture rates</keyword>
	<keyword>immunosuppressive</keyword>
	<keyword>regimen</keyword>
</DOC>